Investor Presentaiton

Financials Market Capitalisation Rs. 1,170 billion / US$ 17 billion. FY14 YOY FY15 SUN PHARMA (All Figures in Rs. Mn) YOY FY16 YOY FY17 YOY FY18 YOY P&L Summary Sales 1,60,044 Gross Profit 1,32,250 EBITDA 71,141 45% 42% 2,72,451 44% 2,05,059 77,208 70% 2,78,881 2% 3,02,642 9% 2,60,659 -14% 55% 2,15,577 5% 2,21,335 3% 1,86,413 -16% 9% 75,594 -2% 87,751 16% 51,846 -41% Net Profit 31,415 5% 45,394 44% 45,457 0% 69,644 53% 21,616 -69% Net Profit (Adjusted) 56,589 # 59% 47,771 # -16% 52,309 # 9% 69,644 33% 33,665 # -52% R&D Spend 10,418 48% 19,550 88% 23,025 18% 23,138 0% 22,489 -3% BS Summary Mar'14 Shareholders Funds 1,85,250 YOY Mar'15 24% 2,80,415 YoY Mar'16 51% 3,29,825 YOY Mar'17 18% 3,66,397 YoY Mar'18 11% 3,81,006 YoY 4% Loan Funds 24,890 75,724 204% 83,164 10% 80,910 -3% 97,518 21% Net Fixed Assets 58,242 15% 96,848 Investments 27,860 16% 35,028 66% 1,24,130 26% 18,298 28% 1,49,404 20% 1,57,110 5% Cash and Bank Balances 75,902 87% 1,09,771 45% 1,31,817 -48% 11,919 20% 1,51,408 -35% 71,430 499% 15% 99,290 -34% Inventory 31,230 21% 56,669 Sundry Debtors 22,004 Sundry Creditors 13,283 -9% 50,928 26% 32,430 131% 81% 64,225 67,757 144% 35,830 13% 68,328 6% 68,810 1% 33% 72,026 6% 78,150 9% 10% 43,954 23% 47,660 8% Exchange Rate : © Sun Pharmaceutical Industries Limited. All Rights Reserved. For Market Capitalisation US$1 = Rs 67.62(As on 31 May 2017) # Adjusted for Rs 25.17 bn provision related to generic Protonix settlement for the year FY14 and adjusted for Rs 2.4 bn for settlement provision for Texas Medicaid Program litigation for FY15 and adjusted for Rs 6.9 bn of exceptional items related to Ranbaxy integration for FY16 and adjusted for Rs 12.1 bn provision related to Modafinil settlement & deferred tax adjustment for the year FY18 45

View entire presentation